Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer

被引：0
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 01期
关键词：
D O I：
10.1016/j.juro.2016.10.035
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
[41]   Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone [J].
Nieblas-Toscano, D. ;
Arenas-Bonilla, A. J. ;
Flores-Martin, J. F. ;
Gutierrez-Tejero, F. ;
Velarde-Munoz, C. ;
Ramos-Alaminos, C., I ;
Salas-Moreno, M. C. ;
Galisteo-Moya, R. ;
Moreno-Jimenez, J. .
ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (03) :164-171
[42]   Chemotherapy for castration-resistant prostate cancer [J].
Berthold, D. .
ONKOLOGIE, 2011, 34 :12-12
[43]   A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC) [J].
Emmenegger, U. ;
Sridhar, S. S. ;
Booth, C. M. ;
Kerbel, R. ;
Berry, S. R. ;
Ko, Y. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[44]   Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer [J].
Christoph W. M. Reuter ;
Michael A. Morgan ;
Philipp Ivanyi ;
Martin Fenner ;
Arnold Ganser ;
Viktor Grünwald .
World Journal of Urology, 2010, 28 :391-398
[45]   Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer [J].
Reuter, Christoph W. M. ;
Morgan, Michael A. ;
Ivanyi, Philipp ;
Fenner, Martin ;
Ganser, Arnold ;
Gruenwald, Viktor .
WORLD JOURNAL OF UROLOGY, 2010, 28 (03) :391-398
[46]   A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC). [J].
Emmenegger, U. ;
Berry, S. R. ;
Booth, C. M. ;
Sridhar, S. S. ;
Winquist, E. ;
Bandali, N. ;
Chow, A. ;
Kerbel, R. ;
Ko, Y. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[47]   Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC) [J].
Emmenegger, U. ;
Berry, S. R. ;
Booth, C. ;
Sridhar, S. S. ;
Winquist, E. ;
Bandali, N. ;
Chow, A. ;
Kerbel, R. S. ;
Ko, Y. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
[48]   Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer [J].
Yuasa, Takeshi .
INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (01) :33-33
[49]   Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel [J].
Ya-nan Man ;
Yan-fang Chen .
International Urology and Nephrology, 2019, 51 :2189-2199
[50]   Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel [J].
Man, Ya-nan ;
Chen, Yan-fang .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (12) :2189-2199
12345